TPST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tempest Therapeutics Inc (TPST) is not a strong buy for a beginner investor with a long-term focus at this time. While the stock has potential upside due to its strategic pivot and analyst upgrade, the company's financial performance is weak, and there are no significant positive trading signals or recent catalysts to justify an immediate investment. Holding off for more clarity on financial improvements or stronger trading signals is recommended.
The technical indicators for TPST are mixed. The MACD is positive and expanding, which is a bullish sign, but the RSI is neutral at 46.878, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 2.319, with support at 2.168 and resistance at 2.47. Overall, the technical setup does not strongly support a buy decision.
Analyst upgrade to 'Buy' with an $11 price target, citing the acquisition of Factor Bioscience's CAR-T programs and a strategic pivot.
Potential for a 6.08% increase in the next month based on historical candlestick patterns.
Weak financial performance in Q3 2025, with a significant drop in net income (-66.74% YoY) and EPS (-85.15% YoY).
Lack of recent news or significant insider/hedge fund activity.
No recent congress trading data or influential figure transactions.
In Q3 2025, Tempest Therapeutics reported no revenue growth (0.00% YoY), a sharp decline in net income (-66.74% YoY), and a significant drop in EPS (-85.15% YoY). Gross margin remained at 0%. The financial performance indicates weak fundamentals.
H.C. Wainwright analyst Joseph Pantginis upgraded TPST to 'Buy' from 'Neutral' with an $11 price target. The upgrade is based on the company's acquisition of Factor Bioscience's CAR-T programs, which is seen as a strategic move to extend its cash runway and expand its pipeline with a clinically de-risked asset.
